Viewing Study NCT02392559

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:43 PM
Ignite Modification Date: 2026-02-05 @ 10:53 PM
Study NCT ID: NCT02392559
Status: COMPLETED
Last Update Posted: 2022-11-08
First Post: 2015-02-25
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Heterozygous Familial Hypercholesterolemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hypercholesterolemia View
None Elevated Cholesterol View
None High Cholesterol View
None Heterozygous Familial Hypercholesterolemia View
None PCSK9 mutations View
None Paediatric View
None pediatric View
None Childhood Familial Hypercholesterolemia View